Trending Now
Inovio Pharmaceuticals Inc. (NASDAQ:INO) Signs Deal With Kaneka Eurogentec For Manufacture...
Inovio Pharmaceuticals Inc. (NASDAQ:INO) has entered a manufacturing deal with Japan's Kaneka Corp to manufacture its COVID-19 vaccine candidate. The US vaccine maker didn't...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Turning Point Therapeutics Inc. (NASDAQ: TPTX) Finalizes Recruitment in EXP-6 Cohort...
Turning Point Therapeutics Inc. (NASDAQ: TPTX) has announced the attainment of its recruitment target of 40 subjects in the EXP-6 cohort of the Phase...
MAKE IT MODERN
LATEST REVIEWS
Searching for Deep Value Opportunities after Key Cannabis Bill Passes House...
Last Friday, we saw something momentous happen: The U.S. House of Representatives passed legislation that aims to take cannabis off the list...
MAKE IT MODERN
PERFORMANCE TRAINING
Twilio Inc (NYSE:TWLO) calls for a technical rally
Futures are down this morning on renewed concerns about the CoronaVirus. New update out of China confirms 254 new deaths and...
Mustang Bio Inc. (NASDAQ:MBIO) Receives Orphan Drug Designation For MB-207 in Treating XSCID patients
Mustang Bio Inc. (NASDAQ:MBIO) has been awarded Orphan Drug Designation for MB-207, its lentiviral gene therapy for treating patients with X-linked severe combined immunodeficiency...
Allena Pharmaceuticals Inc. (NASDAQ: ALNA) Granted Fast Track Designation For Its Oral Urate Degrading...
Allena Pharmaceuticals Inc. (NASDAQ: ALNA) has announced that the FDA has granted its orally delivered, urate degrading enzyme, ALLN-346, a fast track designation.
ALLN-346 is...
Atossa Therapeutics Inc (NASDAQ:ATOS) Reports Tolerability And Safety Of AT-301 In Clinical Trial Phase...
Atossa Therapeutics Inc (NASDAQ:ATOS) reported positive results from the Phase 1 clinical trial of its innovative drug candidate AT-301. Currently, no FDA-approved treatments are...
Inovio Pharmaceuticals Inc (NASDAQ:INO) Receives Funding From DOD And DARPA To Develop dMAb To...
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced the receipt of funding from DOD (Department of Defense) and DARPA (Defense Advanced Research Projects Agency) to develop dMAb.
Preventive...
MAKE IT MODERN
